Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont., May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, today announced the commercial launch of OsteoFactor Pro™, a naturally occurring cocktail of allogeneic growth factors engineered to improve bone healing and support surgical success across orthopedic and spine procedures. ...

STOCKHOLM, SWEDEN, May 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has reached a new milestone with 10,000 patients treated with the innovative nanosynthetic bone graft OssDsign Catalyst on the US market. OssDsign Catalyst is a nanosynthetic bone graft that demonstrates rapid and robust bone formation, even in poorly vascularized environments. Launched in the US in August 2021, OssDsign Catalyst has since achieved significant success in the Amer ...

Core Insights - Kuros Biosciences is set to present its latest developments regarding MagnetOs and its strategic priorities during the Capital Markets Day on May 13, 2025, in Zürich, Switzerland [1][2] Company Overview - Kuros Biosciences is a leader in innovative biologic technologies, focusing on bone healing solutions [1][9] - The company is expanding its global footprint and targeting both spinal and extremity markets, with anticipated growth in the U.S., Europe, and other regions [6] Product Insights - MagnetOs is a proprietary bone healing technology that has shown nearly double the fusion rate compared to autograft in a Level I human clinical study, particularly effective among active smokers [6][7] - The technology utilizes NeedleGrip™, a submicron surface technology that stimulates bone growth without added cells or growth factors [6][7] Strategic Priorities - Kuros aims to improve patient outcomes and drive shareholder value through innovation, strategic partnerships, and global growth [4][6] - The company is leveraging its alliance with Medtronic to enhance market access and accelerate product adoption [6] Clinical Insights - Seven Level I human clinical trials are currently underway to demonstrate MagnetOs' efficacy in promoting bone growth and fusion across various surgical applications [6] - Insights from Dr. Greg Berlet, a leading orthopedic surgeon, will be shared, highlighting the advantages of MagnetOs from both surgeon and patient perspectives [2][6]

Core Insights - Xtant Medical Holdings, Inc. reported a positive net income of $58,000 for Q1 2025, a significant improvement from a net loss of $4.4 million in Q1 2024, indicating a turnaround in financial performance [4][9] - The company achieved an 18% year-over-year revenue growth, reaching $32.9 million, driven by increased sales in orthobiologics and licensing revenue [2][3] - Xtant Medical has raised its revenue guidance for the full year 2025 to between $127 million and $131 million, reflecting an expected growth of 8% to 12% [10] Financial Highlights - Revenue for Q1 2025 was $32.9 million, compared to $27.9 million in Q1 2024, marking an 18% increase [3][9] - Gross margin decreased slightly to 61.5% from 62.1% year-over-year, primarily due to charges for excess and obsolete inventory [3][9] - Operating expenses decreased to $19.2 million in Q1 2025 from $20.8 million in Q1 2024, mainly due to reduced compensation and commission expenses [4][9] Cash Flow and EBITDA - The company generated $1.3 million in operating cash flow in Q1 2025, a turnaround from cash used in operations of $5.8 million in the prior year [2][9] - Non-GAAP adjusted EBITDA for Q1 2025 was $3.0 million, compared to an adjusted EBITDA loss of $1.0 million in Q1 2024 [5][9] Product Development - Xtant Medical launched Trivium™, a next-generation demineralized bone matrix allograft, which is expected to enhance the company's orthobiologics portfolio and drive future growth [2][9] Corporate Developments - The company completed a secondary private sale of existing shares by OrbiMed Advisors LLC, enhancing corporate governance flexibility by terminating the investor rights agreement with OrbiMed [9]

STOCKHOLM, SWEDEN, April 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has notified a change of CEO during the second half of 2025. The purpose is to support the establishment of leadership with an even stronger presence and focus on the US market. OssDsign launched OssDsign Catalyst in the U.S. in August 2021. Since then, the company has undergone a strategic shift to become a pure-play orthobiologics company and has shown high double-digit growt ...